Skip to main content
TipRanks
Go Ultimate75% OFF

Carasent AB (CARA) AI Stock Analysis

0 Followers
SE:CARA

Carasent AB

(Nasdaq OMX AB:CARA)

Select Model
Rating:71Outperform
Price Target:SEK 28.00â–²(11.11% Upside)
Action:upgraded
Date:10/16/26

Carasent's overall score of 71 reflects a company that has successfully pivoted to profitable, cash-generative growth, which is the most significant positive factor. The financial turnaround, underscored by strong cash flow and a debt-free balance sheet, provides a solid foundation. The positive guidance and strong backlog from the earnings call further support the outlook. These strengths are partially offset by a high P/E ratio, which already discounts much of the good news, and a technical picture that, while bullish, is approaching overbought levels. The main operational risks to monitor are the gross margin trend and the execution of the delayed German product launch.

Positive Factors
Recurring growth and retentionStrong group growth, double-digit organic ARR expansion, and net retention above 100% indicate that Carasent is expanding its installed base while growing existing accounts. This supports recurring revenue durability and provides a foundation for continued growth over the next several quarters.
Negative Factors
German churn and execution riskGerman churn in the legacy product directly offsets growth from newer offerings, while the delayed Webcur rollout postpones a potential replacement engine. Together, these issues can restrain regional revenue growth and require sustained execution before Germany becomes a stronger contributor.

Carasent AB (CARA) vs. iShares MSCI Sweden ETF (EWD)

-20%-10%0%10%20%30%SE:CARA-6.49%EWD+16.08%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 1.70B
Dividend Yield
―
Average Volume (3M)
93.23K
Price to Earnings (P/E)
44.0
Beta (1Y)
0.22
Revenue Growth
―
EPS Growth
―
Country
Sweden
Employees
231
Sector
General
Sector Strength
55
Industry
Software - Application

Carasent AB Business Overview & Revenue Model

Company Description

Carasent AB (publ) provides cloud based electronic health record (EHR) systems solutions and platform services for healthcare sector in Nordics and Germany. The company offers Webdoc, Webcur, Metodika, Ad Curis, Ad Opus, and Data-AL solutions. It als...

How the Company Makes Money

Carasent primarily makes money by selling access to its healthcare software products and related services to healthcare organizations. The core revenue model is typically based on recurring fees for software usage (e.g., subscriptions/SaaS-style lice...

Carasent AB Earnings Call Summary

Earnings Call Date:Oct 15, 2026(Q3-2026)|% Change Since:-7.69%|Next Earnings Date:Feb 04, 2027
Earnings Call SentimentPositive

The call was broadly positive, supported by 29% growth, 14% organic ARR growth, improving EBITDA margins, strong sales, healthy net retention, strong year-to-date cash flow and encouraging MedSum and Infosolutions momentum. The main challenges were Germany's delayed Webcur rollout and elevated churn, seasonally and comparably difficult Q4 conditions, planned near-term cost increases, and the slow pace of healthcare technology adoption. Highlights significantly outweighed the lowlights.

Positive Updates

Strong Quarterly Growth and Improved EBITDA Margin
Group growth was 29%, with 14% organic ARR growth and 12% organic revenue growth. EBITDA was SEK 21 million with a 20% margin, up from a 15% margin in the prior year, representing 75% growth.

Negative Updates

Germany Organic Growth and Customer Churn Pressure
Group organic revenue growth was 12%, below the 14% organic ARR growth, with management attributing much of the difference to Germany. Germany has experienced quite significant churn on the old Data-AL product, largely associated with retiring doctors and successors choosing a new system. German churn contributed substantially to group churn, while total churn was SEK 9 million, or 3%/2.8%.

Company Guidance

Management said it will continue to grow strongly, especially in Nordic, pick up the pace in Germany, push Webcur into the market in Q4, and maintain strong cost control; the majority of the backlog will be implemented in Q4, with the Webdoc part implemented within this year, Falck next year, and Frelsesarmeen a bit this year and a bit next year. Medsum’s new functionality is coming around Christmas, with the price staying at roughly SEK 750 per user and month, while MDR certification will require a couple of million in Q4; increased German sales and marketing, including three, four salespeople and other initiatives, will result in around SEK 3 million-SEK 4 million extra cost in the quarter compared to this one, with personnel costs increasing the cost base by a couple of million in Q1 and other effects mostly temporary. Infosolutions will have price increases by New Year and, if it is going according to plan, will next year be among the top companies in the group from a rule of 40 perspective.

Carasent AB Financial Statement Overview

Summary

Carasent demonstrates a strong financial turnaround. Profitability has been restored with a 12% net margin in the TTM period, and revenue growth is robust. The balance sheet is a fortress with minimal debt. Critically, cash flow generation has surged, with operating cash flow far exceeding net income, indicating high-quality earnings. The main concern is the gross margin compression to 69%.

Income Statement

65Positive

Balance Sheet

85Very Positive

Cash Flow

70Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue389.84M343.82M266.90M243.98M195.26M137.13M
Gross Profit260.80M289.00M225.64M197.77M161.42M112.90M
EBITDA86.20M73.34M18.85M2.91M59.11M28.32M
Net Income39.53M34.67M-40.97M-46.45M31.17M-148.00K
Balance Sheet
Total Assets980.79M941.01M1.04B1.09B1.37B1.30B
Cash, Cash Equivalents and Short-Term Investments47.10M139.48M254.05M373.88M694.83M882.77M
Total Debt25.41M31.94M39.95M50.17M38.88M16.34M
Total Liabilities168.17M133.00M173.97M138.24M144.30M129.54M
Stockholders Equity812.62M808.00M865.73M955.41M1.23B1.17B
Cash Flow
Free Cash Flow58.63M-476.00K-4.99M-73.67M-57.95M-5.75M
Operating Cash Flow94.38M40.44M36.58M-4.47M33.61M32.48M
Investing Cash Flow-126.53M-35.98M-116.42M-55.53M-209.50M-125.12M
Financing Cash Flow-93.47M-122.22M-15.88M-263.28M-10.20M756.56M

Carasent AB Technical Analysis

Technical Analysis SentimentNegative
Last Price25.20

Price Trends

50DMA26.46Negative
100DMA25.73Negative
200DMA24.53Positive

Market Momentum

MACD-0.35Positive
RSI37.33Neutral
STOCH13.08Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CARA, the sentiment is Negative. The current price of 25.20 is below the 20-day moving average (MA) of 26.19, below the 50-day MA of 26.46, and above the 200-day MA of 24.53, indicating a neutral trend. The MACD of -0.35 indicates Positive momentum. The RSI at 37.33 is Neutral, neither overbought nor oversold. The STOCH value of 13.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CARA.

Carasent AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

SE:CARA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:LIMESE:LIME79OutperformSEK 3.44B27.9632.20%1.75%8.57%17.98%
SE:UPSALESE:UPSALE78OutperformSEK 431.06M15.80―8.49%11.34%40.60%
SE:VIT.BSE:VIT.B75OutperformSEK 11.65B24.569.27%1.25%5.55%18.93%
SE:CARASE:CARA71OutperformSEK 1.68B44.02――――
SE:ONEFSE:ONEF60NeutralSEK 508.65M-54.39――20.62%85.64%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%

* General Sector Average

Performance Comparison

0%50%100%SE:CARASE:DONESE:LIMESE:VIT.BSE:UPSALESE:ONEFDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:CARA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:CARACarasent AB25.20-1.80-6.67%
SE:DONE24Sevenoffice Scandinavia Ab5.81-0.24-3.97%
SE:LIMELime Technologies AB257.50-49.80-16.20%
SE:VIT.BVitec Software Group AB Class B292.00-6.44-2.16%
SE:UPSALEUpsales Technology AB25.60-3.78-12.86%
SE:ONEFOneflow AB17.95-8.05-30.96%

Carasent AB Corporate Events

Carasent Sets Nomination Committee Ahead of 2027 Annual General Meeting

Oct 19, 2026

Carasent AB has appointed its Nomination Committee for the 2027 Annual General Meeting, following instructions adopted at an Extraordinary General Meeting in 2024. The committee consists of three members representing the company’s largest shareholder...

Carasent Sets Webcast for Release of Q3 2026 Interim Results

Oct 12, 2026

Carasent AB announced that it will publish its interim report for the third quarter of 2026 on October 15 at 07:00 CEST. The company will follow the release with a webcast presentation of the results the same day at 08:00 CEST, offering stakeholders...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 16, 2026